33 Osteogenesis Imperfecta Clinical Trials in New Haven, CT (2026)

Q: How do I join a clinical trial in New Haven?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you.

Recruiting Osteogenesis Imperfecta Studies in New Haven

NCT02418442Recruiting

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARR...

New Haven, CT20,000 participantsDuke University

View Study Details

NCT02474160Recruiting

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

This study collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scie...

New Haven, CT5,000 participantsNational Cancer Institute LAO

View Study Details

NCT06799117Recruiting

Adaptive Decision Support for Addiction Treatment Master

This study refines and optimizes the EMBED\* clinical decision support (CDS; see NCT03658642) to increase number of ED physicians following standard of care for the administration of buprenorphine to ...

New Haven, CTNA1,912 participantsYale University

View Study Details

NCT06465810Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patter...

New Haven, CT1,850 participantsAstraZeneca

View Study Details

NCT07007312Recruiting

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target ...

New Haven, CTPHASE31,300 participantsKura Oncology, Inc.

View Study Details

NCT07207811Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy ...

New Haven, CTPHASE31,280 participantsNovo Nordisk A/S

View Study Details

NCT05579470Recruiting

Expanding Medication-Assisted Therapies in Central Asia

Central Asia (CA) represents the most rapidly growing HIV epidemic region worldwide, concentrated in people who inject drugs (PWID) and their sexual partners, and scaling up opioid agonist therapies (...

New Haven, CTNA900 participantsYale University

View Study Details

NCT07585266Recruiting

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine. It is caused by changes in certain proteins that cau...

New Haven, CTPHASE3800 participantsGlaxoSmithKline

View Study Details

NCT06563895Recruiting

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different orga...

New Haven, CTPHASE3587 participantsEidos Therapeutics, a BridgeBio company

View Study Details

NCT07362082Recruiting

A Clinical Trial of Telehealth Treatment for Opioid Use Disorders

This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder....

New Haven, CTNA470 participantsYale University

View Study Details

NCT07218926Recruiting

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) w...

New Haven, CTPHASE3450 participantsGlaxoSmithKline

View Study Details

NCT05735184Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will inve...

New Haven, CTPHASE1420 participantsKura Oncology, Inc.

View Study Details

NCT06022939Recruiting

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versu...

New Haven, CTPHASE3338 participantsSWOG Cancer Research Network

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

New Haven, CTPHASE2316 participantsTaiho Oncology, Inc.

View Study Details

NCT03816345Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, an...

New Haven, CTPHASE1300 participantsNational Cancer Institute (NCI)

View Study Details

NCT06188585Recruiting

Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding

A prospective, multi-center, noninferiority randomized controlled trial designed to compare the efficacy of UI-EWD (Nexpowder™) hemostatic powder versus conventional endoscopic hemostatic therapy in p...

New Haven, CTNA278 participantsMedtronic - MITG

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

New Haven, CTPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT06800703Recruiting

Opioid Use Disorder and Pain

The goal of this observational study is to characterize the brain processes of pain avoidance learning dysfunctions in individuals with opioid use disorder (OUD). The main questions it aims to answer ...

New Haven, CT180 participantsYale University

View Study Details

NCT03593759Recruiting

Cardiac Sarcoidosis Randomized Trial

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active cli...

New Haven, CTPHASE3160 participantsOttawa Heart Institute Research Corporation

View Study Details

NCT06655246Recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) ...

New Haven, CTPHASE1157 participantsKura Oncology, Inc.

View Study Details

NCT07087054Recruiting

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with ca...

New Haven, CTPHASE3141 participantsCrinetics Pharmaceuticals Inc.

View Study Details

NCT05183035Recruiting

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults wit...

New Haven, CTPHASE3130 participantsPedAL BCU, LLC

View Study Details

NCT07800520Recruiting

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls....

New Haven, CTPHASE1110 participantsYale University

View Study Details

NCT07793383Recruiting

Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 3

This study is stage 2, round 3 of a larger study which refines and optimizes the EMBED clinical decision support (CDS) to increase number of ED physicians following standard of care for the administra...

New Haven, CTNA100 participantsYale University

View Study Details

NCT07086976Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb response (DHR) compared with placebo in approx...

New Haven, CTPHASE390 participantsSanofi

View Study Details

NCT07062588Recruiting

Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)

This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo....

New Haven, CTPHASE280 participantsAngitia Incorporated Limited

View Study Details

NCT07176351Recruiting

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the co...

New Haven, CTPHASE460 participantsYale University

View Study Details

NCT06484062Recruiting

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplast...

New Haven, CTPHASE154 participantsNational Cancer Institute (NCI)

View Study Details

NCT06569147Recruiting

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis....

New Haven, CTPHASE149 participantsBrigham and Women's Hospital

View Study Details

NCT07751991Recruiting

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

The goal of this study is to evaluate the safety of CHM-029, an investigational oral medicine, and to evaluate its activity in treating certain types of acute myeloid leukemia (AML) in adults. The mai...

New Haven, CTPHASE140 participantsCharm Therapeutics

View Study Details

NCT06313437Recruiting

Revumenib in Combination With 7+3 + Midostaurin in AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted th...

New Haven, CTPHASE122 participantsRichard Stone, MD

View Study Details

NCT06160284Recruiting

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET s...

New Haven, CTPHASE112 participantsYale University

View Study Details

NCT06207162Recruiting

Longitudinal Neural Fingerprinting of Opioid-use Trajectories

This project aims to collect a densely sampled neuroimaging dataset among individuals receiving medications for opioid use disorder (MOUD). MOUD is multiphasic, comprised of medication induction, stab...

New Haven, CTNA10 participantsYale University

View Study Details

About Osteogenesis Imperfecta Clinical Trials in New Haven

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 33 osteogenesis imperfecta clinical trials recruiting participants in New Haven, CT. These studies are seeking a combined 37,836 participants. Research is being sponsored by Duke University, National Cancer Institute LAO, Yale University and 18 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in New Haven — FAQ

Are there osteogenesis imperfecta clinical trials in New Haven?

Yes, there are 33 osteogenesis imperfecta clinical trials currently recruiting in New Haven, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Haven?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.

Are clinical trials in New Haven free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 33 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated October 12, 2026 from ClinicalTrials.gov